Enzyme inhibitor blocks respiratory virus replication

Investigators at Imperial College London synthesized the compound IMP-1088, a picomolar dual inhibitor of the human enzymes N-myristoyltransferases NMT1 and NMT2. N-myristoyltransferase catalyzes the transfer of myristate – a rare 14-carbon saturated fatty acid, which is attached by an amide linkage to the N-terminal glycine residue of cellular and viral proteins with diverse functions – from CoA to proteins. Rhinoviruses (RVs) are the pathogens most often responsible for the common cold and are a continual cause of obstacle in asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.
Crystal structures and other affirmation had unveiled those two inhibitors, which the investigators had identified early in their studies, targeted different sites on the human enzymes.A recently crafted drug molecule has ratified to be a potential candidate for the treatment of the viruses stable for the common cold and other respiratory diseases. They used a fragment-based drug design approach to combine the two inhibitors and structure-guided design to optimize the combination agent’s drug properties.
Original Link:https://www.biotechdaily.com/genomics-proteomics/articles/294773637/enzyme-inhibitor-blocks-respiratory-virus-replication.html